Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Thrombocythemia, Essential 2Polycythemia Vera 2Skin Neoplasms 1Philadelphia Chromosome 1Neoplasm, Residual 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Melanoma 1Leukemia, Myeloid, Acute 1Leukemia 1Infections 1Hepatitis C 1Glioma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Brain Neoplasms 1

Interventions

Ribavirin 4ledipasvir, sofosbuvir drug combination 2Sofosbuvir 2telaprevir 1pembrolizumab 1peginterferon alfa-2a 1grazoprevir 1elbasvir-grazoprevir drug combination 1elbasvir 1Rapid Diagnostic Tests 1Immunoenzyme Techniques 1Hypothermia, Induced 1Enzyme-Linked Immunosorbent Assay 1Chromatography, High Pressure Liquid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hepatitis C × peginterferon alfa-2a × Clear all
NCT01821963 2020-09-24

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

M.D. Anderson Cancer Center

Phase 3 Terminated
1 enrolled 3 charts
Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular, Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡